Norgestrel
|
Norgestrel
|
|
| Systematic (IUPAC) name | |
| (8R,9S,10R,13S,14S,17S)- 13-ethyl-17-ethynyl-17-hydroxy- 1,2,6,7,8,9,10,11,12,14,15, 16- dodecahydrocyclopenta[a]phenanthren-3-one | |
| Identifiers | |
| CAS number | |
| ATC code | G03 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C21H28O2 |
| Mol. mass | 312.446 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | 5-14 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Norgestrel is a progestin used in hormonal contraceptives. Norgestrel is a mixture of two stereoisomers, dextro-norgestrel (CAS# 797-64-8) and levo-norgestrel (CAS# 797-63-7). Only levonorgestrel is biologically active. Therefore, while some medications may contain dextronorgestrel, they are often labeled in terms of their levonorgestrel content only, ignoring the inert isomer.
See also
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)


